2251.HK
Bayzed does healthcare

Beijing Airdoc Technology Co. Ltd. (2251.HK) announced on Monday that the China Securities Regulatory Commission (CSRC) has approved its plan to convert 50.15 million of its domestic shares into H-shares that can be publicly traded in Hong Kong. The conversion involves company stock held by 26 shareholders.

Airdoc was founded in 2015 as a provider of ophthalmic imaging solutions. Last July it announced the development of its Wanyu Medical Large Model, expanding its services from single-image diagnostics to general medical Q&A and health management. This February, it upgraded the Wanyu model and integrated it with the DeepSeek R1 model.

Airdoc’s revenue fell 23.3% year-on-year to 156 million yuan ($21 million) last year, while its net loss widened significantly from 133 million yuan in 2023 to 255 million yuan last year. The company’s shares have plunged 83.22% since their listing in November 2021, including a 7.95% decline this year.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Illustration of Hong Kong as a ipo pipeline and crypto lab for China

Hong Kong: China’s IPO pipeline and crypto lab

Companies raised $13.6 billion through Hong Kong IPOs in the first half of the year, giving the city the global fundraising title for that period. What's behind the sudden boom? And a growing number of Chinese companies are experimenting with cryptocurrencies in Hong Kong, even as such currencies are banned on the Mainland. What's driving such different approaches on the Mainland and in Hong Kong?